Target intelligence / Profile preview

SRI antisense RNA 1 (SRI-AS1)

Target
SRI-AS1
Molecular classification
Long non-coding RNA, Antisense RNA, Non-coding RNA
01

Overview

SRI antisense RNA 1 (SRI-AS1) is classified as a long non-coding antisense RNA transcribed from the region opposite the SRI (Sorcin) gene locus. Like other natural antisense RNAs, its primary function is the regulation of gene expression, typically by hybridizing with the complementary sense mRNA, influencing its stability, translation, or epigenetic state. While the general mechanisms and significance of antisense RNAs (asRNAs) in cellular processes and disease are well supported, the specific functions and disease associations of SRI-AS1 in particular are not yet well elucidated in the literature. Generally, antisense lncRNAs are increasingly studied for their emerging roles in cancer (often as regulators of oncogenes and tumor suppressors), and for their potential as research tools or therapeutic targets. However, SRI-AS1 is not currently considered a classical therapeutic target such as a receptor or enzyme: it is a gene regulatory RNA, not a protein-coding gene[1][2][3].

Other names
SRI-AS1SRI antisense RNAnatural antisense transcript at SRI locus
02

Mechanism of action

Antisense-mediated regulation—hybridization to complementary mRNA(s) to modulate stability, translation, or chromatin structure of the sense gene product

03

Biological functions

Regulation of gene expression, likely at the transcriptional or post-transcriptional level; typical for antisense RNAs but specific functions for SRI-AS1 may not be fully characterized
04

Disease associations

Potentially implicated in cancer, based on emerging roles of antisense lncRNAs in cancer biology; specific associations for SRI-AS1 are not well established
05

Safety considerations

None specific; generic challenges apply to modulating non-coding RNAs, such as off-target effects and delivery challenges

Beyond the preview

Go deeper on SRI antisense RNA 1 (SRI-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRI antisense RNA 1 (SRI-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call